Halozyme announces notice of allowance for patent claims to second human enzyme.
"We are pleased to add these new natural and recombinant composition of matter claims in the '283 patent to Halozyme's growing human enzyme intellectual property estate," said Gregory Frost, PhD, Halozyme's Chief Scientific Officer. "This second enzyme can be readily channeled into our commercially validated molecular engineering systems and mammalian manufacturing processes, and fits nicely with Halozyme's demonstrated ability to develop and commercialize recombinant human enzymes."
Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the infertility, palliative care, and oncology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may replace current animal slaughterhouse-derived extracts that carry potential risks of animal pathogen transmission and immunogenicity. The company has received FDA approval for two products: Cumulase, the first and only recombinant human hyaluronidase for cumulus removal in the IVF process; and Hylenex, for use as an adjuvant to increase the absorption and dispersion of other injected drugs. The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent, and therapeutic drug.
Halozyme Therapeutics, Inc.
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Jan 1, 2006|
|Previous Article:||Patent office awards 7 millionth patent to DuPont for bio-based material.|
|Next Article:||Roche and Applied Biosystems settle PCR litigation with Bio-Rad.|
|Enzyme offers promise of Alzheimer's drugs.|
|GlycoDesign receives patent allowance for cancer drug.|
|HALOZYME THERAPEUTICS REITERATES ENHANZE SC TIMELINE.|